Randomized, Double‐Blind, Placebo‐Controlled Phase II Study of Yeast‐Brachyury Vaccine (GI‐6301) in Combination with Standard‐of‐Care Radiotherapy in Locally Advanced, Unresectable Chordoma

Overview of attention for article published in Oncologist, March 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (78th percentile)
Above-average Attention Score compared to outputs of the same age and source (61st percentile)

Mentioned by

twitter: 8 X users
patent: 1 patent

facebook: 2 Facebook pages

Readers on

mendeley: 69 Mendeley

So far, Altmetric has seen 11 X posts from 8 X users, with an upper bound of 45,376 followers.

RT @OncJournal: Randomized, Double‐Blind, Placebo‐Controlled Phase II Study of Yeast‐Brachyury Vaccine (GI‐6301) in Combination with Standa…

Randomized, Double‐Blind, Placebo‐Controlled Phase II Study of Yeast‐Brachyury Vaccine (GI‐6301) in Combination with Standard‐of‐Care Radiotherapy in Locally Advanced, Unresectable Chordoma #Chordoma #Immunotherapy #TherapeuticVaccine #RadiationTherapy …

RT @ChrisHeery: This trial serves a lot of purposes for the @ChordomaFDN community. We now have a prospective control for a number of endpo…

This trial serves a lot of purposes for the @ChordomaFDN community. We now have a prospective control for a number of endpoints. We also are learning what other mechanisms need to be addressed for immunologic targeting of chordoma cells in patients. @so…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 7 additional X posts.